Percutaneous aspiration and sclerotherapy for simple hepatic cysts: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: symptomatic simple hepatic cysts (SHCs)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, given the high risk of bias in the available evidence and the lack of direct comparison with surgical treatment, these findings should be interpreted with caution. Further high-quality comparative studies are warranted to confirm these results.
[PURPOSE] This systematic review aims to assess the efficacy and safety of percutaneous aspiration and sclerotherapy (PAS) for patients with symptomatic simple hepatic cysts (SHCs).
- 95% CI 80.2-91.6
- 연구 설계 systematic review
APA
Matsumoto T, Yoshimatsu R, et al. (2026). Percutaneous aspiration and sclerotherapy for simple hepatic cysts: a systematic review and meta-analysis.. Japanese journal of radiology, 44(1), 168-182. https://doi.org/10.1007/s11604-025-01874-7
MLA
Matsumoto T, et al.. "Percutaneous aspiration and sclerotherapy for simple hepatic cysts: a systematic review and meta-analysis.." Japanese journal of radiology, vol. 44, no. 1, 2026, pp. 168-182.
PMID
41026438
Abstract
[PURPOSE] This systematic review aims to assess the efficacy and safety of percutaneous aspiration and sclerotherapy (PAS) for patients with symptomatic simple hepatic cysts (SHCs).
[MATERIALS AND METHODS] We systematically searched the electronic databases of PubMed, Embase, the Cochrane Library and Ichushi-Web for studies published up to November 2024, reporting outcomes of PAS for symptomatic SHCs. The primary outcomes were rates of symptomatic relief or disappearance of symptoms. The secondary outcomes were cyst volume reduction rates and complication rates. Subgroup analyses compared ethanol with the other sclerosants. Single-arm meta-analyses were performed, with meta-regression conducted when substantial heterogeneity (I > 50%) was observed. Risk of bias was assessed using the Cochrane RoB2 tool for randomized controlled trials and RoBANS2 for non-randomized studies.
[RESULTS] Sixteen studies were included. Fourteen studies were assessed as having a high risk of bias. The pooled symptomatic relief or disappearance rate was 86.9% (95% CI 80.2-91.6%, I = 0%). The cyst volume reduction rate was 86.4% (95% CI 74.1-93.3%, I = 95%). There were no major complications. The pooled minor complication rates were 13.6% (95% CI 6.5-26.4%, I = 67.2%) for pain and 7.4% (95% CI 4.1-13.0%, I = 38%) for fever. Subgroup analysis showed no significant differences between ethanol and other sclerosants. High heterogeneity was observed for cyst volume reduction and pain, indicating variability across studies. Meta-regression analysis for cyst volume reduction rate and pain did not identify any significant associations.
[CONCLUSION] PAS appears to be a relatively safe and effective treatment option for patients with symptomatic SHCs and provides high rates of symptomatic relief with low complication rates. However, given the high risk of bias in the available evidence and the lack of direct comparison with surgical treatment, these findings should be interpreted with caution. Further high-quality comparative studies are warranted to confirm these results.
[MATERIALS AND METHODS] We systematically searched the electronic databases of PubMed, Embase, the Cochrane Library and Ichushi-Web for studies published up to November 2024, reporting outcomes of PAS for symptomatic SHCs. The primary outcomes were rates of symptomatic relief or disappearance of symptoms. The secondary outcomes were cyst volume reduction rates and complication rates. Subgroup analyses compared ethanol with the other sclerosants. Single-arm meta-analyses were performed, with meta-regression conducted when substantial heterogeneity (I > 50%) was observed. Risk of bias was assessed using the Cochrane RoB2 tool for randomized controlled trials and RoBANS2 for non-randomized studies.
[RESULTS] Sixteen studies were included. Fourteen studies were assessed as having a high risk of bias. The pooled symptomatic relief or disappearance rate was 86.9% (95% CI 80.2-91.6%, I = 0%). The cyst volume reduction rate was 86.4% (95% CI 74.1-93.3%, I = 95%). There were no major complications. The pooled minor complication rates were 13.6% (95% CI 6.5-26.4%, I = 67.2%) for pain and 7.4% (95% CI 4.1-13.0%, I = 38%) for fever. Subgroup analysis showed no significant differences between ethanol and other sclerosants. High heterogeneity was observed for cyst volume reduction and pain, indicating variability across studies. Meta-regression analysis for cyst volume reduction rate and pain did not identify any significant associations.
[CONCLUSION] PAS appears to be a relatively safe and effective treatment option for patients with symptomatic SHCs and provides high rates of symptomatic relief with low complication rates. However, given the high risk of bias in the available evidence and the lack of direct comparison with surgical treatment, these findings should be interpreted with caution. Further high-quality comparative studies are warranted to confirm these results.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.
- High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection.
- Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.
- A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis.
- A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol.